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Worldwide, around 14 million individuals are coinfected with both tuberculosis (TB) and human immunodeficiency virus (HIV).
In coinfected individuals, both pathogens weaken immunological system synergistically through mechanisms that are not fully
understood. During bothHIV andTB infections, there is a chronic state of inflammation associated to dramatic changes in immune
cytokine and endocrine hormone levels. Despite this, the relevance of immunoendocrine interaction on both the orchestration of
an effective immune response against both pathogens and the control of the chronic inflammation induced duringHIV, TB, or both
infections is still controversial.The present study reviews immunoendocrine interactions occurring during HIV and TB infections.
We also expose our own findings on immunoendocrine cross talk in HIV-TB coinfection. Finally, we evaluate the use of adrenal
hormones and their derivatives in immune-therapy and discuss the use of some of these compounds like the adjuvant for the
prevention and treatment of TB in HIV patients.
1. Introduction
Worldwide, around 14 million individuals are believed to be
coinfected with both tuberculosis (TB) and human immun-
odeficiency virus-1 (HIV-1), constituting together the leading
infectious diseases in resource-limited countries [1].
The African region accounted for most of the HIV-
infected TB cases, and TB is the first cause of death in AIDS
context [1, 2]. Also, HIV coinfection raises latent TB reacti-
vation risk by 20-fold, becoming the leading risk factor for
Mycobacterium tuberculosis (Mtb) infection progression to
active disease [1, 3]. Likewise, TB exacerbates HIV infection
progression [4, 5].Therefore, the intersecting HIV and tuber-
culosis epidemics in countries with a high disease burden of
both infections pose many challenges and opportunities.
In coinfected individuals,Mtb and HIV, weaken immun-
ological system synergistically, disrupting immune functions
through mechanisms that are not fully understood.
An extendedTB treatment (6months) is required to erad-
icate Mtb infection, rising up to 9 months for HIV patients
[6]. While replicating bacilli are killed by anti-TB drugs
during the first weeks of treatment, Mtb evades drugs and
host-immune responses by successfully adapting to a quies-
cent physiological state [7]. In the absence of chemotherapy
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treatment, immune system failure, among other factors, leads
to TB relapse [8].Therefore, amore effective and shorter trea-
tment may require the modulation of the immune response
towards a protective phenotype. Actually, several immune
modulation strategies, like vitamin D supplement [9], treat-
ment withTh1 cytokines [10, 11], and immune suppression to
disrupt granulomas and make bacteria more susceptible to
chemotherapy [12], among others, have been explored with
diverse results [13].
Endocrine and immune systems are strictly connected by
multiple mutual regulatory pathways, the most extensively
studied of which is the anti-inflammatory and immune-sup-
pressive action of glucocorticoids (GCs). Several cytokines
have been found to regulate the endocrine system and many
steroid and nonsteroid hormones have shown immunomod-
ulatory effects [14–17].
In a broad range of bacterial, viral, and parasitic infec-
tions, the immune response developed against the pathogen
is paralleled by a significantly altered hormonal response both
in experimental models and human patients [18]. In fact,
there is some evidence that supports a role for the interaction
between immune and endocrine systems in the orchestration
of an effective defense against the infectious agents [18, 19].
Despite this, the relevance of the cross talk between immune
and endocrine systems on the defense against infections has
not been fully elucidated.
The classical view stands that proinflammatory cytokines
(mostly IL-1𝛽, IL-6, TNF-𝛼, and IFN-𝛼/𝛽) produced in
response to pathogens induce the hypothalamic-pituitary-
adrenal (HPA) axis for the release ofGCs [14, 18]. In turn,GCs
suppress the immune system at several levels, avoiding the
possible adverse effects of an exacerbated immune response
and helping to terminate it once the injurious agent was
cleared [20]. However, although true for some particular situ-
ations like acute inflammation, the viewofGCs such as simple
immune suppressors has been changed, as there is growing
evidence showing that GCs may be both pro- and anti-
inflammatory, and also even necessary for several immune
processes [20].
On the other hand, the activation of HPA axis induces the
release of other adrenal hormones, like dehydroepiandros-
terone (DHEA) and DHEA-sulphate (DHEA-s), with known
anti-GC functions [21]. GCs and DHEA have opposite effects
on adaptive immune cells. While GCs inhibit both Th1 and
Th2 cytokines by activated human T cells, its effect on Th1
cytokines is more pronounced, shifting T cell response
towardsTh2profiles [22]. On the contrary, DHEApromotes a
shift towardsTh1 responses by skewing cytokine production,
upregulatesTh1 cytokines like IL-2 and IFN-𝛾, and downreg-
ulates Th2 cytokines like IL-4 and IL-5 [23]. In line with this,
DHEA and its derivatives have been proved to enhance pro-
tective immune responses against several pathogens [24–27].
During infection, immune-endocrine interactions are
even more complex, since pathogens per se can modulate
endocrine function either by releasing soluble factors or by
directly colonizing endocrine tissue [28, 29]. Furthermore,
specific treatments like antibiotics may affect hormonemeta-
bolism [30]. Moreover, during chronic infections like HIV or
TB, in which pathogens are not cleared and immune response
must be sustained in time, there is a chronic state of inflam-
mation associated to dramatic changes in immune cytokine
and endocrine hormone levels [29, 31]. Despite this, the
relevance of immunoendocrine interaction on both the orch-
estration of an effective immune response against both patho-
gens and the control of the chronic inflammation is still
controversial.
The present study reviews immunoendocrine interac-
tions occurring during HIV and TB infections. In addition,
we expose our own findings on immunoendocrine cross talk
in HIV-TB coinfection. Finally, we evaluate the use of adrenal
hormones and their derivatives in immune-therapy and
discuss the use of some of these compounds like the adjuvant
for the prevention and treatment of TB in HIV patients.
2. Immunoendocrine Alterations during
Human Tuberculosis
Initial infection withMtb occurs upon inhalation of airborne
droplets containing bacilli, which, once in the lungs, infect
and reside mainly in myeloid cells, especially alveolar macro-
phages [7]. In most people, such initial infection resolves, or
it is kept under control by the development of an appropriate
adaptive immune response that prevents bacillary prolifera-
tion and dissemination.
Effective control ofMtb infection relies on cell-mediated
immunity [32]. Once in the infected tissue, T cells produce
interferon gamma (IFN-𝛾) in response tomycobacterial anti-
gen presentation by antigen presenting cells and consequently
IFN-𝛾 activates macrophages to kill intracellular bacteria
[33, 34]. In addition to CD4+ T cells, which are thought
to be the most important, both CD8+ T cells [35, 36] and
CD1-restricted unconventional T cells [37] contribute to the
effective control of Mtb infection. Both CD8+ T cells and
CD1-restricted unconventional T cells are thought to be par-
ticularly important in the prevention of latent TB reactivation
[35–38].
Moreover, at least 30% of the persons that take contact
with Mtb remain persistently infected without exhibiting
signs of disease in a state known as latent TB infection (LTBi)
[39]. While infection may persist for life, bacillary growth
may be reactivated in 5–10% of non HIV-infected subjects,
probably due to factors affecting the host’s immune status,
and postprimary disease ensues [7]. As described above,
in HIV-infected persons this rate rises to 20%. Persistent
infection with Mtb is accompanied by chronic, low-level
inflammation, which together drive to several changes in cyt-
okine and hormone levels.
TB patients show a twofold increase in IFN-𝛾 and IL-10
and a 10-fold increase in IL-6 plasma levels, accompanied by
a 50% decrease in testosterone and DHEA in plasma when
compared to healthy controls [40]. Also, TB patients show
higher diurnal peaks of cortisol [41] and higher cortisol res-
ponses to ACTH stimulation [42], showing that HPA axis is
activated in these patients. Since GCs enhance Th2 activity,
HPA axis control may be relevant to theTh1/Th2 balance dur-
ing the establishment of the anti-infectious immune response
[33, 34, 43]. Conversely, DHEA can directly and indirectly
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enhance Th1 T cell activity [21]. According to this, Mtb-
specific IFN-𝛾 secretion in TB patients correlated positively
with DHEA plasma levels and inversely with cortisol/DHEA
ratio [44].
In addition to proinflammatory cytokines, regulatory
cytokines such as TGF-𝛽 are likely involved in the control of
some endocrine functions during TB infection. For instance,
in vitro treatment of the human adrenal cell line NCI-H295-R
with culture supernatants ofMtb-stimulated PBMC from TB
patients inhibited DHEA and induced cortisol secretion [40].
Of note, treatment with anti-TGF-𝛽 antibodies abolished the
inhibitory effect on DHEA but not cortisol secretion [45].
Overall, the hormonal changes occurring during Mtb
infection could prevent the development of protective imm-
une responses and the control of persistent inflammation.
3. Immunoendocrine Interactions in
HIV Infection
HIV-1 infection is accompanied by a strong innate and adap-
tive immune response, beside which it remains as a chronic
infection through lifetime.
The main obstacle for HIV eradication is the establish-
ment of a latent HIV reservoir, which occurs during the very
early stages of primary infection. Virus genomic integration
and latency, as well as an enormous genetic diversity, propel a
constant immune escape which limits HIV-specific immune
response efficacy, especially during the early events of infec-
tion.
HIV infection causes the depletion of CD4+ T cells,
which accounts formost infection hallmark symptoms. Addi-
tionally, a systemic and chronic immune activation and an
accelerated T cell turnover are also thought to contribute to
HIV disease progression [46]. Finally, the constant antigenic
stimulation is thought to induce T cell dysfunction in res-
ponse to antigen stimulation [47].
Despite the persistent immune escape seen in the great
majority of HIV-infected people, there are rare individuals
who control HIV-1 burden to undetectable levels.These indi-
viduals, known as elite controllers, show HIV-specific CD8+
T cells with higher cytotoxic capacity [48, 49] and are also
associated to some specific MHC class I alleles [50]. In line
with this, HIV infection progression was suggested to be
associated with a reduction in cellular immunity, that is, Th1,
and an increase inTh2 cytokine production [51, 52].
Considering that GCs provoke a shift from Th1 to Th2
immunity and also alter the balance between Th17 and Treg
cells [53], recently implicated in the pathogenesis of HIV
[54], HPA axis activation could play a central role in the pro-
gression of HIV infection to disease. In fact, increased basal
ACTH and/or cortisol levels in 50% of HIV-infected patients
accompanied by an impaired ACTH and cortisol response
to stress and CRH challenge, especially in advanced disease,
have been reported [55, 56]. The proposed mechanisms to
this hypercortisolemia include a shift in steroidogenesis from
DHEA and aldosterone to cortisol and the stimulation of
hypothalamus, pituitary, and adrenal cortex by cytokines [56,
57].Moreover, the stimulation of theHPA axismay also result
from the stimulatory effects of viral proteins, like the HIV
envelope protein gp-120 and the structural protein viral pro-
tein R (Vpr)which have been shown to increase serumACTH
and to cause GCs hypersensitivity, respectively [58–60].
HIV-infected patients show a characteristic pattern of
high cortisol and low DHEA-s levels [61], which have been
associated with a negative course of disease [55, 61]. In fact, it
has been shown that DHEA-s levels decline with the progres-
sion of the disease in parallel with the CD4 T cell count [61].
Immune system deterioration in HIV-infected patients with
high cortisol/DHEA-s levels seems to be associated with the
suppression of Th1 cytokines and the concomitant increase
in Th2 cytokines levels [62]. In line with this, it has been
suggested that cortisol-resistant HIV-infected patients have
a prominent Th1 cytokine profile and, therefore, present a
limited progression to AIDS [63, 64].
4. Immunoendocrine Alterations Observed in
HIV-TB Coinfection
There is limited data available about the role of adrenal
steroids on the immune response developed by patients coin-
fected with HIV-1 andMtb. We determined DHEA, DHEA-s,
and cortisol plasma levels and the role of these adrenal hor-
mones on Mtb-specific Th1 responses and Treg frequencies
in patients dually infected with Mtb and HIV undergoing
different stages of Mtb infection [65]. We observed that,
in HIV-infected patients with active TB (HIV-TB), DHEA
plasma levels were diminished by twofold compared to HIV-
infected patients withoutMtb coinfection or healthy donors.
On the contrary, HIV-infected patients latently infected with
Mtb (HIV-LTBi) showed preserved DHEA levels. Addition-
ally, while cortisol plasma levels were slightly higher in HIV-
TB patients than in HIV patients, cortisol/DHEA ratio was
almost 4 times higher in HIV-TB patients compared to HIV,
HIV-LTBi, and healthy donors. Of note, in HIV-TB patients,
DHEA-s levels correlated positively, while cortisol plasma
levels correlated negatively with CD4+ T cell count. More-
over, we observed an inverse correlation between DHEA-s
plasma levels and Treg frequency in the same group.
A remarkable finding of this study was the persistent
observation of a conspicuous CD4+CD25−FoxP3+ popula-
tion in HIV-TB patients that was not observed in the other
groups. Notably, CD4+CD25−FoxP3+ population is also
increased in systemic lupus erythematosus patients [66], but
its nature remains undetermined. Some authors suggested
that these cells are FoxP3+ non-Treg T cells [67], whereas
others argue that these cells are dysfunctional Treg cells with
limited regulatory potential [68].
In order to clarify this, we evaluated FoxP3 liability in
these cells by keeping themunstimulated for different periods
of time. By doing this, we observed that within these cells
Foxp3 expression was relatively stable, suggesting that, at
least in HIV-TB patients, the intriguing CD4+CD25−FoxP3+
population is not a transiently activated effector population
and rather might have regulatory functions [67, 68]. We
hypothesize that this unusual regulatory populationmay pre-
clude protective immune responses againstMtb in our cohort
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of coinfected patients, a topic currently under investigation
by our group. Finally, we also found that the frequency
of CD4+CD25−FoxP3+ cells in HIV-TB patients negatively
correlated with DHEA plasma levels, which is consistent
with a role of DHEA on enhancing Th1 responses while
diminishing this particular regulatory T cell population.
Moreover, we also found that the initiation of antituber-
culous treatment (ATT) diminished CD4+CD25−FoxP3+,
which was restored to normal levels after finalization of treat-
ment. In contrast, conventional CD4+CD25+FoxP3+ Tregs
in HIV-TB patients tended to diminish across visits, but not
significantly. In HIV-TB patients, adrenal hormone balance
was not restored as well, at least after 6 months of ATT
(unpublished results).
In some HIV-infected patients, the recovery of specific
immune responses during the beginning of highly active
antiretroviral treatment (HAART) can elicit systemic inflam-
matory responses which lead to the establishment of the
immune reconstitution inflammatory syndrome (IRIS). In
HIV-TB IRIS patients, DHEA-s plasma levels were three
times lower and cortisol/DHEA ratio was up to four times
higher compared to the non-TB groups. The CD4+CD25−
FoxP3+ frequency was also increased in IRIS patients and
negatively correlated with DHEA-s plasma levels [65].
Previous results obtained by our research group also
showed a positive correlation between DHEA plasma levels
and the frequency of a terminally differentiated population
of CD8+ T cells in HIV-TB patients, which is thought to be
crucial in preventing TB reactivation (in press and [38]). We
also observed that in vitro DHEA treatment increased Mtb-
specific CD8+ T cell proportions and terminal differentiation
in CD8+ T cells of HIV-TB coinfected patients. Additionally,
we found that DHEA in vitro increased the expression of
the transcription factor Tbet and Tbet/Eomesodermin ratio
in isolated CD8+ cells, both known to drive to terminal
differentiation in CD8+ T cells [69].
Based on our results, in HIV-TB coinfected patients, HPA
axis displays a noticeable alteration, probably influenced by
the chronic state of inflammation induced by both pathogens
concomitantly.This conditionmay contribute to the immune
system dysfunction seen in these patients.
5. Adrenal Steroids in Immunotherapy
As suggested by the evidence depicted above, DHEA seems to
have two different functions regarding immune modulation:
it favorsTh1 responses, fundamental in the protection against
intracellular pathogens like Mtb and HIV, and, on the other
hand, it exerts anti-inflammatory actions, which may be
beneficial in the context of chronic infection. For that reason,
DHEA has been proved as an adjuvant therapy for the treat-
ment of several infectious diseases.
The apparent dual function of DHEA, together with the
fact that a cell receptor is not known for it, suggests that this
hormone may exert its immune regulatory function through
some of its metabolites, which are known to be potent
immune-regulators in vivo [26]. DHEA is the physiological
precursor for the synthesis of androgens and estrogen, but
it can also be metabolized into oxygenated derivatives in
nonsteroidogenic tissues, especially in human liver [70].
There is also evidence that DHEA can be converted into
oxygenated derivatives like 3𝛽,17𝛽-androstenediol (AED)
and 3𝛽,16𝛽,17𝛽-androstenetriol (AET) by monocyte-derived
macrophages [71].
In mice, DHEA and AED were protective against lethal
dose of Pseudomonas aeruginosa or Enterococcus faecalis inf-
ection. Both steroids appeared to act on immune system
rather than bacteria directly, since the growth of bacterium
was not altered in in vitro assays [72]. DHEA, AET, and AED
also proved to protect mice against lethal doses of human
herpes type 2 or coxsackievirus B4 [26, 72] while DHEA
supplementation enhanced the immune response against
Trypanosoma cruzi in mice, as shown by a significant reduc-
tion in parasitemia levels [73].
A synthetic derivate from DHEA, 16𝛼-Bromoepiandros-
terone (HE2000), has been tested in animal models of TB
[25]. In these sets of experiments, HE2000 proved to reduce
bacterial load associated with progressive TB and lowered
IL-4 expression associated withMtb infection. Also, BALB/c
mice with active TB treated with HE2000 showed lower
bacterial proliferation and a higherTh1/Th2 cytokine balance.
The treatment with HE2000 also resulted in lower percent-
ages of lungs involved in pneumonia and higher bacterial
clearance, when administered as an adjunct to conventional
chemotherapy [25].
The above mentioned evidence suggests that DHEA and
its derivate upregulate host immunity, leading to higher resis-
tance to infectious agents. In line with this, treatment of mice
with AET augmented the absolute numbers of CD4+/CD8+
T cells after irradiation and increased IL-2, IL-3, and IFN-
𝛾 levels counteracting hydrocortisone immune suppression
[26]. Additionally, zinc and DHEA supplementation augme-
ntedmacrophage count and IFN-𝛾 andNO concentrations in
an additive manner [24].
Despite the above mentioned immune-enhancing effects
ofDHEA, the effect of this steroid onT cell function is contro-
versial. While some researchers showed that DHEA enhan-
ced T cells proliferation and IL-2 production [70], others
reported the contrary [74]. A posterior study suggested that
DHEA acted differentially on T and B lymphocytes, since it
significantly inhibited proliferation of T cells, but, on the
other hand, increased B cell mitogen pokeweed mitogen
(PWM) effect on PBMC [75].
Experiments performed by our group demonstrated that
DHEA induced the increment in the production of IL-
12 and reduced IL-10 secretion by Mtb-stimulated human
monocyte-derived dendritic cells (DCs) promotingTh1 resp-
onses [76]. Also, DHEA enhanced the expression of MHC I,
MHC II, and CD86 and increased ERK1/2 phosphorylation.
Furthermore, DHEA enhanced the antigen-specific T cell
proliferation and IFN-𝛾 production induced by Mtb-stimu-
lated DCs.
DHEA synthetic derivate, HE2000, also proved to be
beneficial in human infection. A pilot study showed a 50%
reduction in Plasmodium falciparum blood levels in 41 out
of 42 patients enrolled, thereafter achieving undetectable
parasitemia levels in 76% of them [77]. A randomized,
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double-blind, placebo-controlled study showed that HE2000
administration induced significantly sustained decreases in
IL-1𝛽, TNF-𝛼, IL-6, and Cox-2 transcripts and although
CD4+ T cell numbers remain unaltered, patients demon-
strated a significant decrease in viral load and a significant
increase in CD8+ T cell responses after HE2000 administra-
tion [27]. Noteworthy, as shown by another study, HE2000
lowered by 42.2% the incidence of tuberculosis coinfection in
AIDS patients while also reduced the cumulative incidence
of opportunistic infections [78]. Unfortunately, despite the
positive results obtained in phase I and II studies, currently
there are no ongoing clinical trials exploring the effects of
HE2000. Finally, at present we are studying the modulatory
features of 7-oxo-DHEA, a DHEA natural derivative, on the
immune response against TB in the context of HIV infection.
6. Concluding Remarks
Immune endocrine interactions during infectious diseases
may determine the failure or success of the immune response.
This is particularly true for chronic infections like HIV or
TB, in which pathogens and immune system coexist in a
long struggle. Here we show the importance of DHEA and its
derivatives on immunity to intracellular pathogens like HIV
andMtb through its action onTh1 and CD8 responses.These
compounds also exert anti-inflammatory actions, which may
be beneficial in the context of chronic infections, especially
during HIV-TB coinfection.
This dual function of DHEA makes it very suitable as an
immune-therapy for the prevention and treatment of TB in
the context of HIV infection.
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